Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval

Shortly after an FDA nod for a chemotherapy combination in newly diagnosed non-small cell lung cancer, Regeneron’s Libtayo has registered another seemingly positive readout in the same setting—this time with extra help from Bristol Myers Squibb’s Yervoy. But this one won’t matter commercially.